SenzaGen AB Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
|
27/06 | Transcript : SenzaGen AB - Special Call | |
15/05 | SenzaGen AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 67.35M 6.35M 529M | Sales 2025 * | 91.85M 8.66M 722M | Capitalization | 211M 19.9M 1.66B |
---|---|---|---|---|---|
Net income 2024 * | -11M -1.04M -86.45M | Net income 2025 * | 1M 94.34K 7.86M | EV / Sales 2024 * | 2.78 x |
Net cash position 2024 * | 23.8M 2.25M 187M | Net cash position 2025 * | 22M 2.08M 173M | EV / Sales 2025 * | 2.06 x |
P/E ratio 2024 * |
-14.9
x | P/E ratio 2025 * |
-44.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.78% |
Latest transcript on SenzaGen AB
Managers | Title | Age | Since |
---|---|---|---|
Peter Nählstedt
CEO | Chief Executive Officer | 50 | 01/18/01 |
Marianne Olsson
DFI | Director of Finance/CFO | 63 | 01/16/01 |
Henrik Johansson
CTO | Chief Tech/Sci/R&D Officer | 42 | 01/14/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 76 | 18/10/18 | |
Director/Board Member | 59 | 15/14/15 | |
Paula Zeilon
BRD | Director/Board Member | 62 | 01/20/01 |
1st Jan change | Capi. | |
---|---|---|
-41.38% | 8.21B | |
+7.89% | 3.55B | |
-2.03% | 2.24B | |
-27.06% | 1.86B | |
-21.74% | 1.68B | |
+11.83% | 940M | |
+24.25% | 751M | |
-12.66% | 667M | |
+1.19% | 286M |